Clinical Results Presented at Turkish Medical Congress Further Support LuViva® Advanced Cervical Scan for Primary Screening and Detection of Cervical Cancer

Guided Therapeutics Announces Pricing of $3.8 Million Public Offering

Nigerian Clinical Studies Demonstrate Advantages of LuViva® Advanced Cervical Scan for Screening and Detecting Cervical Pre-Cancer in Africa

Guided Therapeutics Reports Third Quarter 2014 Results

Guided Therapeutics to Report Third Quarter 2014 Results and Hold Conference Call

Guided Therapeutics Announces Initial $200,000 Investment from Turkish Distributor, ITEM Medical Technologies Group

Guided Therapeutics to Present at Rodman & Renshaw 16th Annual Global Investment Conference on Wednesday, September 10th

Guided Therapeutics Initiates Cervical Cancer Screening Trial for LuViva® Advanced Cervical Scan

Guided Therapeutics Reports Second Quarter 2014 Results

Guided Therapeutics to Report Second Quarter 2014 Results and Hold Conference Call

Guided Therapeutics Files PMA Amendment with FDA for LuViva® Advanced Cervical Scan

Guided Therapeutics Granted Additional Key Patent for LuViva® Advanced Cervical Scan

Guided Therapeutics’ LuViva® Advanced Cervical Scan Awarded Mexican Regulatory Approval

Guided Therapeutics Second Quarter Sales to Reach $200,000; Update Timing for Amended PMA Application for LuViva® Advanced Cervical Scan

Guided Therapeutics’ LuViva® Advanced Cervical Scan Wins Prestigious Medical Design Award

Guided Therapeutics to Present at LD Micro Invitational Conference on Wednesday, June 4

Guided Therapeutics to Present at Annual Marcum MicroCap Conference on Thursday, May 29

Guided Therapeutics’ LuViva® Advanced Cervical Scan Detected 100% of Precancers in New Blinded Clinical Study Presented at an International Cervical Pathology and Colposcopy Conference

Guided Therapeutics Announces Completion of Private Placement of Senior Convertible Notes

Guided Therapeutics Reports First Quarter 2014 Results

Guided Therapeutics Set to File Amended PMA Application for LuViva® Advanced Cervical Scan After “Productive” Face-to-Face Meeting with FDA

Guided Therapeutics to Report First Quarter 2014 Results and Hold Conference Call

Guided Therapeutics Announces Private Placement of up to $3,000,000 in Senior Convertible Notes

Guided Therapeutics Receives May 8th Meeting Date from FDA to Discuss LuViva® Advanced Cervical Scan PMA Application

Guided Therapeutics’ LuViva® Honored as Finalist in the Medical Device Excellence Awards

Guided Therapeutics Submits Request for Face to Face Meeting with FDA; Receives Notification on PMA Extension for LuViva® Advanced Cervical Scan

Guided Therapeutics Reports Fourth Quarter and 2013 Results

HPV Screening Beneficial for Guided Therapeutics’ LuViva® Advanced Cervical Scan in Developed Countries; No Anticipated Impact in Developing Countries

Guided Therapeutics to Report Fourth Quarter 2013 Results and Hold Conference Call

New Clinical Study Results of Guided Therapeutics’ LuViva® Advanced Cervical Scan to be Presented by Key Opinion Leaders at Top International Medical Conference

Guided Therapeutics Names Gene Cartwright as Chief Executive Officer